Professor Michel Michaelides

NHS secretary: 

Rachel Sappor

Consultant telephone: 

020 7566 2011

Area(s) of specialism / subspecialism: 


  • Medical retina and inherited eye disease (adults and children)


Year of first medical qualification: 


Further key experience: 

  • Medical retina fellowship, Moorfields Eye Hospital
  • Ocular genetics and paediatric ophthalmology fellowships, Casey Eye Institute, Oregon, USA
  • Doctor of Medicine research degree in inherited retinal dystrophies from University College London

Date joined Moorfields: 

2005 - as a registrar; 2010 - as a consultant

Membership of professional /national/regional bodies: 

  • Fellow, Royal College of Ophthalmologists, London
  • Fellow of the American College of Surgeons
  • Member, American Academy of Ophthalmology
  • Member, Association for Research in Vision & Ophthalmology
  • Member, European Society of Retina Specialists
  • Member, European Paediatric Ophthalmological Society

Current NHS/university posts, whether full/part time, and starting year: 

  • Consultant ophthalmic surgeon, Moorfields Eye Hospital (2010)
  • Clinical senior lecturer in Ophthalmology, UCL Institute of Ophthalmology (2010)

Other professional achievements: 

  • Elected to The Macula Society (2013)
  • Foundation Fighting Blindness (USA) career development award (2011)
  • International guest scholar, American College of Surgeons (2010)
  • Department of Health/HEFCE ‘new blood’ senior lectureship award (2010)
  • Senior resident, Moorfields Eye Hospital (2007)

Research interests: 

  • New treatments for retinal disease including diabetic retinopathy and genetic eye disease such retinitis pigmentosa and Stargardt disease
  • My long-term vision and goals include: 
  • (i) Optimizing the clinical care of patients with retinal disease including: 
  • (ii) Establishing a molecular genetic diagnosis in the majority of patients with inherited eye disease, helping to improve counselling, advice on prognosis, and identify patients with molecularly proven disease who may be eligible for current and future treatment trials. 
  • (iii) Identify patients / genetic subtypes and time-points, which may be most appropriate for treatments, and identify reliable and sensitive outcome measures. 
  • (iv) Assisting in the development of gene- and non-gene directed therapies to either significantly slow / halt disease progression or ideally improve visual function and subsequently being the clinical lead in undertaking rigorous clinical trials to ascertain their efficacy.

Languages spoken: 


  • English
  • Greek

Any other personal interests/background information that may be relevant: 

  • Travel
  • Scuba diving
  • Swimming